# Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer

Source: https://onco.cc/trials/nct02674568/  
OnCo record `nct02674568` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rovalpituzumab tesirine in Small-cell lung cancer, run by AbbVie, completed.

## Summary

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer is a phase 2 interventional study registered as NCT02674568 by AbbVie, with 342 participants recorded, started 2016-01-25 and reaching its primary completion in 2018-10-19. Interventions recorded: Rovalpituzumab tesirine. Conditions recorded: Small Cell Lung Cancer.

Linked to the drug Rovalpituzumab tesirine because the registry names it among its interventions and Small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02674568
- Phase: 2
- Setting: An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
- Sponsor: AbbVie
- Enrolled: 342

## Sources

- ClinicalTrials.gov NCT02674568: https://clinicaltrials.gov/study/NCT02674568

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Rovalpituzumab tesirine](https://onco.cc/drugs/rovalpituzumab-tesirine/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct02674568.json